Press and Media
Parenteral manufacturing is always a challenging process due to cost and competitive pressures, but a Restricted Access Barrier System (RABS) may provide a solution.
Pharmaceutical and biotech companies are increasingly under pressure to meet the many challenges of highly competitive markets, the loss of patent protection, competition from generic drugs, and the threat of biosimilars. Reducing costs and optimizing processes while at the same time, developing and marketing innovative drugs quickly and successfully puts additional pressure on companies to get it right the first time. In this issue of PharmaPro, Joerg Zimmerman, Vetter’s Director Process Development and Implementation offers insight into one option that might help manufactures optimize these processes and help lower costs – the Restricted Access Barrier Systems (RABS) for filling of aseptic parenteral syringes.